Novo Nordisk (NVO) Thursday said it plans to significantly reduce the list price paid by US customers for its Tresiba and Fiasp insulin products starting January 2026.
The price of vials and pre-filled injector pens of the company's fast-acting Fiasp insulin will drop 75%, matching the price of its Novolog insulin, while the price of various dispensers of its long-acting Tresiba insulin analog will fall by 72.2%, making it 20% lower than its unbranded equivalent, insulin degludec, the Danish drugmaker said.
Novo Nordisk will cease production of its unbranded insulin biologicals by the end of 2025 and said it wanted to provide healthcare professionals, wholesalers and insurers with more than 12 months advance notice to ensure a smooth transition for patients.
Price: 108.87, Change: -0.10, Percent Change: -0.09
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。